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packets). The most widely kept medicines are medicines for the central nervous system 
(21%), the disorders in the digestive system and metabolism (16.7%) and medicines 
for the diseases of the respiratory system (14.5%). Nearly three-fourths of opened 
packets were not entirely consumed. a large number of medicines in home pharmacies 
(79%) was obtained self initiatedly and many of them were beyond their expiry date 
(9.5%). a total of 25% of the ﬁ nancial means for those medicines was provided from 
health insurance funds. The total cost of medicines in home pharmacies per a family 
in Serbia was c25.13. a total of 72% of that amount was paid by the patients 
themselves. Pharmacoeconomic indicators in certain groups of medicines show that 
the largest percentage of the ﬁ nancial means for home pharmacies in Serbia is spent 
on the medicines for gastrointestinal problems and metabolism disorders (17%). 
CONCLUSIONS: Based on the analyzed data, self-medication, that is, unreasonable 
use of medicines, is a big problem in Serbia. The use of these medicines involves the 
risk of inadequate treatment of the illness, frequent occurrence of side-effects which 
sometimes requires additional treatment, which only increases the expenses for both 
the patients and health funds. Therefore, it is necessary to closely monitor the issuing 
of prescriptions as well as educate the population.
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PRIMARY HEALTH CARE AND POTENTIALLY AVOIDABLE 
ADMISSIONS: A 10-YEAR ASSESSMENT FROM THE PERSPECTIVE OF A 
HEALTH CARE PLAN
Reis Neto J, Tovar C
CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil
OBJECTIVES: To examine the evolution of the rate of admissions for ambulatory 
care sensitive conditions in beneﬁ ciaries of a health care plan, monitoring of access to 
the health system and its performance and identifying strategies that will enable the 
improvement of the health situation of the population and the appropriate allocation 
of resources. METHODS: Retrospective analysis of 212,360 hospital admissions, 
occurring between 1999 and 2008, among beneﬁ ciaries of a health care plan, resident 
in Brazil. The outcome of the study was the proportion of admissions for primary 
care sensitive conditions, identiﬁ ed by ICD-10. The proportion of these admissions in 
relation to the total hospital admissions was established, as well as the quotient for 
the number of hospital admissions and the population, either total or by age group 
and speciﬁ c causes, besides hospital direct costs. The signiﬁ cance was tested and 
estimates of the rates were deﬁ ned based on their 95% conﬁ dence intervals. RESULTS: 
Admissions for primary care sensitive conditions accounted for 55,307 of 212,360 
admissions reimbursed by the health plan (26.0%). The rate of admission for primary 
care sensitive conditions fell by 28.0% during the period (from 347.6 to 250.3 per 10 
thousand). The most frequent cause was gastroenteritis (30.9%), followed by arterial 
hypertension (13.6%), cerebrovascular diseases (9.6%), heart failure (8.1%), kidney 
and urinary tract infections (6.8%), diabetes mellitus (5.8%) and angina pectoris 
(5.5%). The mean annual expenditure on admissions was R$15,232,494 against 
R$51,440,680 for other conditions (22.8%). CONCLUSIONS: The reduction 
observed in the rate of admissions for primary care sensitive conditions suggests pos-
sible improvements in primary health care. Further actions and strategies could reduce 
the number of avoidable admissions and contribute to the ﬁ nancial balance of the 
health care plan.
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EVALUATION OF THE IMPACT OF INPATIENT CLINICAL PHARMACY 
SERVICES ON THE QUALITY AND COST OF PHARMACOTHERAPY IN 
INTERNAL MEDICINE WARDS
Pitakthum S
Songkhla Hospital, Songkhla, Thailand
OBJECTIVES: The purpose of this longitudinal descriptive study was to evaluate the 
inﬂ uence of interventions by clinical pharmacists on processes, outcomes of care and 
economical outcomes. METHODS: The patients who were hospitalized at internal 
medicine wards, Songkhla hospital during October 1, 2008-September 30, 2009 were 
recruited to this study. The core set of clinical pharmacy services were admission drug 
histories, drug protocol management, adverse drug reaction management, drug infor-
mation, medical rounds and patient discharge counseling. The clinical pharmacists 
collected patients’ data, pharmacists’ interventions, direct drug cost-saving and activi-
ties on a speciﬁ c designated form. The data was processed on a computerized database. 
Clinical pharmacist interventions were counted and classiﬁ ed and analyzed to deter-
mine the inﬂ uence on the quality and cost of pharmacotherapy. Descriptive statistics 
were used in data analysis. RESULTS: At the end of the study period the following 
were found: a total of 3796 patients were recruited. Clinical pharmacy services on 
internal medicine wards contribute to maximizing the pharmacotherapeutic effect and 
rationalization of drug therapy in 609 patients (16.0%), increase medication safety in 
338 patients (8.9%) and reducing drug expenditures in 575 patients (15.1%). Cost-
saving from reconciling process was US$12,682 and cost-saving from pharmacists’ 
interventions were US$6,298. The frequent type of interventions was maximizing the 
pharmacotherapeutic effect (40.8%), rationalization of drug therapy (30.3%) and 
minimizing the risk for developing adverse drug effects (28.9%), respectively. The top 
two of drug related problems found in cardiovascular drugs (30.5%) and antibiotic 
drugs (24.8%), respectively. CONCLUSIONS: The results of this study indicate that 
inpatient clinical pharmacy services on internal medicine wards contribute to ratio-
nalization of drug therapy, increase medication safety and reduced the direct expen-
ditures on medications. Therefore, future studies should include multiple sites such as 
in a general surgical department and clinical pharmacy services should be 
continued.
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OBJECTIVES: Funding for health care programs competes with funding for professional 
education (ie, implementation of health care programs) and funding for research to 
reduce uncertainty around program cost-effectiveness. No study has yet shown how to 
allocate a combined budget for health care, professional education, and research. Previ-
ous work did not consider the fundamental idea that interventions with an acceptable 
incremental cost-effectiveness ratio (ICER) for an adoption decision may not be accept-
able any more once implementation decisions are made simultaneously. Furthermore, 
previous work did not consider that cost-effectiveness of research is conditional upon 
the programs chosen for adoption and implementation. The purpose of this work is to 
present a sequential process to allocate a combined budget with the goal to maximize 
health. METHODS: Development of a 3-step allocation process to maximize health 
based on a single budget for health care, professional education, and research RESULTS: 
As a ﬁ rst step, a league table approach determines which programs would be funded if 
the combined budget were spent just on adoption. The second step analytically deter-
mines a new (lower) threshold ICER which maximizes health by discontinuing programs 
above the new threshold and investing in implementing programs below the threshold. 
The third step considers cost-effectiveness of research to reduce uncertainty around 
program cost-effectiveness. In order to fund this research, the threshold ICER for adop-
tion plus implementation has to be reduced further. In order to maximize health, ICERs 
of research studies need to equal the newly deﬁ ned threshold ICER for adoption plus 
implementation. CONCLUSIONS: A 3-step allocation process is able to maximize 
health based on a single budget for health care, professional education, and research. 
Compared to a programming approach the proposed approach yields a closed-form 
analytical solution and is able to consider that research decisions are conditional upon 
adoption and implementation choices.
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DIRECT CONTRACTS ON PATENT-PROTECTED PHARMACEUTICALS 
IN GERMANY: MOTIVES OF SICK FUNDS AND PHARMACEUTICAL 
COMPANIES
Neurohr C, Huebner S, Ernst F, Welte R
GlaxoSmithKline GmbH & Co. KG, Munich, Germany
OBJECTIVES: To investigate the motives of both contracting parties, sick funds and 
pharmaceutical companies, to enter into direct contracts on patent-protected pharma-
ceuticals in the outpatient sector in Germany. METHODS: A systematic literature 
review was performed in March 2010 to identify contracts on patent-protected phar-
maceuticals in Germany. Standard literature databases such as Pubmed and EMBASE, 
different market research databases and the ‘Lauer-Taxe’, the ofﬁ cial German price 
registry for pharmaceuticals were utilised. We included only ofﬁ cially reported contracts. 
a detailed market analysis was conducted to identify the motives of the identiﬁ ed con-
tracts. RESULTS: The number of direct contracts has been recently increasing. a total 
of 116 contracts were found. Formally, they are all rebate contracts due to German law. 
However, they include risk-sharing (n = 6), cost-sharing (2), added value (5) and simple 
rebate contracts (103). For sick funds, major motives were cost cutting, positioning 
within the market, attracting the “right” members, improving the medical treatment 
and right coding. Pharmaceutical companies show several motives that can be clustered 
into proactive and reactive motives: Proactive motives were: gaining access to reimburse-
ment beyond standard coverage, funding of managed care concepts, bridging a time gap 
until market entry of a successor, maintaining the attractiveness after patent expiration 
as well as shaping the market access environment. Reactive motives were: rebate con-
tracts of competitors, limitations and exclusions from reimbursement by the federal joint 
committee as well as reacting to attempts by sick funds and Associations of Statutory 
Health Insurance Physicians to control drug expenditures. CONCLUSIONS: Direct 
contracting on patent-protected pharmaceuticals seems to play a increasing role in the 
strategic considerations of pharmaceutical companies and sick funds.
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A TALE OF FOUR COUNTRIES: COMPARING REIMBURSEMENT 
SUBMISSION REQUIREMENTS IN IRELAND, ENGLAND, WALES AND 
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OBJECTIVES: Requirements for a Health Technology Assessment (HTA) submission vary 
within the UK (England and Wales [National Institute for Health and Clinical Excellence 
(NICE)], Scotland [Scottish Medicines Consortium (SMC)], and Wales [All Wales Medi-
cines Strategy Group (AWMSG)]) and the Republic of Ireland (National Centre for 
Pharmacoeconomics [NCPE]). The objective of this study is to determine whether the 
likelihood of reimbursement in these markets is linked to HTA submission requirements. 
METHODS: Dossier requirements issued by NCPE, NICE, SMC and AWMSG were 
compared, and a checklist of requirements compiled. We investigated 20 interventions 
most recently reviewed by the NCPE, and recorded the recommendations for these com-
pared with those issued by NICE, SMC and AWMSG. RESULTS: Economic analysis is 
key for an NCPE submission, although there are no speciﬁ c requirements or template for 
the clinical data. Requirements for NICE are the most stringent; SMC and AWMSG have 
similar requirements. Of 20 interventions reviewed by NCPE, 11 (55%) were reimbursed 
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under the Community Drugs Scheme. Of these, 2 treatments were reimbursed after a price 
reduction, 2 were borderline, and 1 treatment was cost-effective under the General Medical 
Services scheme but not the Drugs Payment Scheme. Of the 11 products reimbursed by 
NCPE, 5 were recommended by NICE (45%), 6 by SMC (55%) and 1 by AWMSG (9%). 
Not all of the 11 treatments were reviewed by NICE, SMC and/or AWMSG. Furthermore, 
2 of the 11 treatments have been withdrawn in Scotland, England and Wales. Limited 
clinical/economic data was the reason for the one non-recommendation by the SMC. a 
more detailed analysis will be presented. CONCLUSIONS: Although requirements for 
HTA submissions vary between countries, demonstrating cost-effectiveness is a key factor 
for reimbursement in all markets investigated.
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REFINING INPATIENT PSYCHIATRIC FACILITY REIMBURSEMENT: 
LESSONS FROM OTHER MEDICARE PROSPECTIVE PAYMENT SYSTEMS
Pierce CA, Jones NA, Brocketti JJ
The Resource Group, Richﬁ eld, OH, USA
OBJECTIVES: The Inpatient Psychiatric Facility Prospective Payment System (IPF 
PPS) is the youngest of the Medicare PPSs. Inpatient Psychiatric Facilities (IPFs) were 
excluded from the acute care inpatient diagnosis-related groups (DRG) system as it 
was thought to be a poor predictor of resource use for psychiatric patients. Although 
the IPF PPS was to include a patient classiﬁ cation system to reﬂ ect the differences in 
resource use and costs among IPFs, it was implemented without an associated assess-
ment tool. This project reviews Medicare PPSs in which diagnosis is not an adequate 
predictor of resource use; compares data collected via the related assessment instru-
ments, and discusses applicability to the IPF PPS. METHODS: The Medicare prospec-
tive payment systems were evaluated and the relevant systems isolated. The systems’ 
deﬁ ning criteria were deﬁ ned and the related assessment instruments explored for 
identifying measures. RESULTS: Under the current IPF PPS, Medicare pays for the 
per diem costs associated with furnishing covered inpatient psychiatric services via a 
nationally established base rate adjusted by geographic, facility and patient factors. 
Patient characteristics are limited to seventeen Medicare severity-diagnosis related 
groups (MS-DRGs), age, length of stay and certain co-morbidities but, unlike home 
health, skilled nursing and rehabilitation facility systems, do not account for functional 
status or other contributors to resource consumption. CONCLUSIONS: Patients in 
IPFs may vary in care needs despite common MS-DRG classiﬁ cation, thus require 
different resources. With limited ability to adjust beyond primary diagnosis, the 
current IPF PPS may misalign facility payment and expenses, ultimately impacting 
access to care. By analyzing other Medicare PPSs policy makers may positively con-
tribute to the reﬁ nement of this newest system.
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EFFECTS OF REFERENCE PRICING AND TENDER CONTRACTS IN 
GERMANY
Volmer T1, Fieke H2
1TV Healthcare Consulting, Hamburg, Germany; 2University Muenster, Muenster, Germany
OBJECTIVES: The therapeutic reference price (RP) system in Germany is regarded as 
a successful mechanism to reduce pharmaceutical spending. However, later introduced 
price directed measures such as the so-called payer contracts (pharmaceutical tender 
contracts (TC) interact with the reference price mechanism. The aim of this paper is to 
compare and analyze the effects of both instruments on pharmaceutical price, volume 
and expenditure for substances at the period around loss of exclusivity. METHODS: a 
group of frequently prescribed drugs with patent expiry between the years of 2001 and 
2008 are investigated and the sales and unit data in the statutory health insurance system 
are analyzed for a period one year before and two year post patent expiry. RESULTS: 
The data show for the group with reference price and no tender contract (RP+/TC-) and 
with no reference price but tender contracts (RP-/TC+) similar level for the sales but 
signiﬁ cantly higher volume data for the ﬁ rst group. In the ﬁ rst year post patent expiry 
there seams to be a signiﬁ cant drop of sales and volume 9–12 month post patent expiry—
a period, when usually the reference price is set. The ﬁ gures for the groups with tender 
contracts (TC+) show a more steadily decline post patent expiry. The group RP+/TC+ 
is in terms of cost containment (sales decline) the most prominent one. If no regulation 
takes place, sales and volume increases even post patent expiry. CONCLUSIONS: Refer-
ence pricing and tender contracts are two cost containment measures, which are equally 
effective if applied alone, and which have additional impact, when applied together.
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EFFECTS OF THE POTENCIAL GENERIC SUBSTITUTION IN PORTUGAL. 
DOES REGULATION MATTERS?
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OBJECTIVES: Considering the pharmaceutical expenditure trend and the current eco-
nomic and social context in Portugal, this study aims to: 1) analyze the national and 
international policy environments in Europe and US, concerning INN prescription and 
generic substitution, and 2) calculate the effect of generic substitution in Portugal, in terms 
of savings for the NHS and patients. METHODS: We conducted an international legisla-
tion review and generics market data. We estimated annual savings under the assumption 
of gradual increase in generics market share, and considering the difference between 
branded and generic medicines prices for each group of the Reference Price System (RPS). 
The database includes sales from Portuguese community pharmacies. RESULTS: The INN 
prescription is allowed in 20 countries of all 27 European countries and in all 50 US states. 
The generic substitution by pharmacists is allowed in 21 European countries (mandatory 
in 8) and in all US states (mandatory in 14). Despite the high increase from 2002, generics 
market share in Portugal is still below the European average, furthermore with a slowdown 
in its growth since 2005. The doctors prescribed 39.1% of drugs by brand name with no 
permission for substitution in 2009. The simulations generated savings of c120.4 million 
(50.8 for the NHS and c69.6 million for patients), less 11.1% of the medicines expenditure 
covered by the RPS. CONCLUSIONS: The market shares observed seem to reﬂ ect the 
different legislative frameworks. In Portugal, despite the growing share of generics, there 
is still a large potential market with signiﬁ cant opportunities of additional savings for the 
health system and patients, and may contribute to a higher pharmaceuticals accessibility 
as well to maximize therapeutic adherence.
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ASSESSMENT OF PHARMACEUTICAL EXPENDITURE TRENDS IN 
PORTUGAL—PRICING AND REIMBURSEMENT POLICY
Teixeira I, Mendes Z
CEFAR—Center for Health Evaluation Studies, Lisboa, Portugal
OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the annual growth of public expenditure in 1% for drugs reim-
bursed in outpatient sector. Considering the 10.4% increased in pharmaceutical 
expenditure from the National Health Service (NHS) in the ﬁ rst 4 months of 2010, 
this study aims to identify the main factors of expenditure growth and implications 
of legislative modiﬁ cations in Portugal. METHODS: We have considered the policy 
changes concerning pricing and reimbursement and analyzed the database that 
includes sales from Portuguese community pharmacies and drugs prescription data. 
The statistical analysis of monthly data by product was performed with Statistical 
Analysis System (SAS), version 8.2. RESULTS: The new legislation approved in June 
2009, that establishes the generics reimbursement at 100% for pensioners whose 
income is below the national minimum wage was responsible for more c20.4 million 
of NHS spending in 2010. The special reimbursement regimes had also contributed 
positively for this trend: for example, the reimbursement rate raise for some anti-
asthmatics (from 37% to 69%) was responsible for c5.1 million (10.3%) of NHS 
expenditure increase. Nevertheless c10.7 million (21.5% of NHS expenditure growth) 
are explained by the top 10 branded drugs recently reimbursed (5 oral antidiabetics 
and 1 insulin). The reform in reimbursement system approved for July 2010 also 
predicts major changes in the expenditures trends. CONCLUSIONS: The legal frame-
work has a high impact in pharmaceuticals expenditures trends, and consequently in 
public ﬁ nancial burden and patient co-payments. The different policy measures 
adopted should be assessed on a periodic basis in order to monitor the market dynam-
ics and to identify the strategies that support the sustainable expenditure growth.
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EFFECTS OF COST-CONTAINMENT METHODS TO DRUG PRICE LEVEL 
IN EUROPE
Ligeti I, Komáromi T
Healthware Ltd, Budapest, Hungary
OBJECTIVES: Due to the dynamic increase of pharmaceutical expenditure in the last 
decade different cost-containment method has been introduced by the European public 
insurance companies. The cost-effective drug reimbursement system might inﬂ uence 
the price level either in a direct or an indirect way, so the pricing strategy should be 
based on demand drivers and on factors of the regulatory environment as well. The 
goal of this analysis was to identify the effect the certain reimbursement solutions and 
local market characteristic on average price level of the predeﬁ ned submarket. 
METHODS: Before the statistical analysis we have built a comprehensive, standard-
ized and continuously updated international drug database based on ofﬁ cial sources 
which supported the analysis trough getting wider access to data’s. Because of the 
expected domestic introduce of international reference price system, we handled it 
with an extra attention among the explanatory variables. RESULTS: The variance of 
international pharmaceutical price level by the examined submarket found to be 
remarkable which can be explained by the difference product supply and the different 
apply of cost-containment methods of price regulation. CONCLUSIONS: The most 
effective way to curb the increased expenditure by the patient and the public insurance 
companies seems to be international reference price system; however the effect of this 
method differs across the countries.
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A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING 
RESTRICTIONS
Wilk NM
Arcana Institute, Krakow, Malopolskie, Poland
OBJECTIVES: Increasingly difﬁ cult situation of health care systems forces decision 
makers to limit access to publicly funded drugs compared to registration conditions. 
To keep the transparency, the decisions to deny health intervention to some group of 
patients have to be publicly justiﬁ ed—simple intuition is not enough. The objective is 
to present initial classiﬁ cation and details of methods to generate public funding 
restrictions. METHODS: A pool of public funding decisions has been identiﬁ ed 
through search of internet websites of the institutions that recommend or actually 
make public funding decisions. The speciﬁ c conditions restricting the access were 
identiﬁ ed, grouped and further analyzed together with their justiﬁ cation if available. 
RESULTS: All restrictions generally aim to optimize the performance of the decision 
